Published in AIDS Res Hum Retroviruses on May 01, 1997
The contribution of peroxynitrite generation in HIV replication in human primary macrophages. Retrovirology (2007) 0.93
Peroxynitrite decomposition catalyst prevents apoptotic cell death in a human astrocytoma cell line incubated with supernatants of HIV-infected macrophages. BMC Neurosci (2002) 0.80
Incomplete APOBEC3G/F Neutralization by HIV-1 Vif Mutants Facilitates the Genetic Evolution from CCR5 to CXCR4 Usage. Antimicrob Agents Chemother (2015) 0.79
Novel in vivo model for the study of human immunodeficiency virus type 1 transcription inhibitors: evaluation of new 6-desfluoroquinolone derivatives. Antimicrob Agents Chemother (2007) 0.76
Studies in subjects with long-term nonprogressive human immunodeficiency virus infection. N Engl J Med (1995) 5.69
A novel procedure for quantitative polymerase chain reaction by coamplification of competitive templates. Gene (1992) 3.48
Phase I studies of 2',3'-dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternating with zidovudine (AZT). Lancet (1988) 3.37
Genetic control of the CD4/CD8 T-cell ratio in humans. Nat Med (1995) 2.75
In vivo activity against HIV and favorable toxicity profile of 2',3'-dideoxyinosine. Science (1989) 2.70
European guidelines on the clinical management of HIV-1 tropism testing. Lancet Infect Dis (2011) 2.47
Analysis of HIV-1 load in blood, semen and saliva: evidence for different viral compartments in a cross-sectional and longitudinal study. AIDS (1996) 2.41
Microarray application in prenatal diagnosis: a position statement from the cytogenetics working group of the Italian Society of Human Genetics (SIGU), November 2011. Ultrasound Obstet Gynecol (2012) 2.38
Quantitative PCR and RT-PCR in virology. PCR Methods Appl (1993) 2.20
Pregnancy outcome following maternal exposure to statins: a multicentre prospective study. BJOG (2012) 2.14
High vitamin A intake in early pregnancy and major malformations: a multicenter prospective controlled study. Teratology (1999) 2.12
Evaluation of prenatal ultrasound diagnosis of fetal abdominal wall defects by 19 European registries. Ultrasound Obstet Gynecol (2001) 2.10
Sexual transmission of the hepatitis C virus and efficacy of prophylaxis with intramuscular immune serum globulin. A randomized controlled trial. Arch Intern Med (1997) 1.92
Absolute quantitation of viremia in human immunodeficiency virus infection by competitive reverse transcription and polymerase chain reaction. J Clin Microbiol (1992) 1.85
Molecular profile of human immunodeficiency virus type 1 infection in symptomless patients and in patients with AIDS. J Virol (1992) 1.80
A human binding site for transcription factor USF/MLTF mimics the negative regulatory element of human immunodeficiency virus type 1. Virology (1992) 1.72
Evaluation of LRRK2 G2019S penetrance: relevance for genetic counseling in Parkinson disease. Neurology (2007) 1.61
Recombination hotspot in NF1 microdeletion patients. Hum Mol Genet (2001) 1.61
Searching for psoriasis susceptibility genes in Italy: genome scan and evidence for a new locus on chromosome 1. J Invest Dermatol (1999) 1.50
1,2,3-Triazole-[2',5'-bis-O-(tert-butyldimethylsilyl)-beta-D- ribofuranosyl]-3'-spiro-5"-(4"-amino-1",2"-oxathiole 2",2"-dioxide) (TSAO) analogues: synthesis and anti-HIV-1 activity. J Med Chem (1994) 1.50
Identification of a SUFU germline mutation in a family with Gorlin syndrome. Am J Med Genet A (2009) 1.49
Relative potency of protease inhibitors in monocytes/macrophages acutely and chronically infected with human immunodeficiency virus. J Infect Dis (1998) 1.47
Highly specific inhibition of human immunodeficiency virus type 1 by a novel 6-substituted acyclouridine derivative. Biochem Biophys Res Commun (1989) 1.46
Prenatal detection of congenital renal malformations by fetal ultrasonographic examination: an analysis of 709,030 births in 12 European countries. Eur J Med Genet (2005) 1.45
How wide is the clinical spectrum of the acrocallosal syndrome? Report of a mild case. J Med Genet (1990) 1.44
Safety of nevirapine-containing antiretroviral triple therapy regimens to prevent vertical transmission in an African cohort of HIV-1-infected pregnant women. HIV Med (2006) 1.43
Hemophilia and nonprogressing human immunodeficiency virus type 1 infection. Blood (1997) 1.41
Factors determining the activity of 2',3'-dideoxynucleosides in suppressing human immunodeficiency virus in vitro. Mol Pharmacol (1988) 1.38
Defective intracellular transport and processing of OA1 is a major cause of ocular albinism type 1. Hum Mol Genet (2000) 1.38
Human case of autochthonous West Nile virus lineage 2 infection in Italy, September 2011. Euro Surveill (2011) 1.35
Genetic analysis in Italian families with inflammatory bowel disease supports linkage to the IBD1 locus--a GISC study. Eur J Hum Genet (1999) 1.32
Homozygous delta 32 deletion of the CCR-5 chemokine receptor gene in an HIV-1-infected patient. AIDS (1997) 1.32
Increasing prevalence of non-clade B HIV-1 strains in heterosexual men and women, as monitored by analysis of reverse transcriptase and protease sequences. J Acquir Immune Defic Syndr (2001) 1.31
Preparation and characterization of an intravenous solution of IgG from human immunodeficiency virus-seropositive donors. Blood (1991) 1.30
Oxidative stress and neuroAIDS: triggers, modulators and novel antioxidants. Trends Neurosci (2001) 1.30
Updated European recommendations for the clinical use of HIV drug resistance testing. Antivir Ther (2004) 1.28
Dynamics and modulation of human immunodeficiency virus type 1 transcripts in vitro and in vivo. J Virol (1996) 1.27
Detection of human immunodeficiency virus type 1 genomic RNA in plasma samples by reverse-transcription polymerase chain reaction. J Med Virol (1991) 1.26
Evaluation of prenatal diagnosis of congenital heart diseases by ultrasound: experience from 20 European registries. Ultrasound Obstet Gynecol (2001) 1.25
Mental retardation and cardiovascular malformations in NF1 microdeleted patients point to candidate genes in 17q11.2. J Med Genet (2004) 1.25
Dissection of human humoral immune response against hepatitis C virus E2 glycoprotein by repertoire cloning and generation of recombinant Fab fragments. Hepatology (1998) 1.21
Mapping B-cell epitopes of hepatitis C virus E2 glycoprotein using human monoclonal antibodies from phage display libraries. J Virol (2001) 1.19
N-Acetylaspartate reduction as a measure of injury severity and mitochondrial dysfunction following diffuse traumatic brain injury. J Neurotrauma (2001) 1.19
Eicosapentaenoic acid (EPA) reduces crypt cell proliferation and increases apoptosis in normal colonic mucosa in subjects with a history of colorectal adenomas. Int J Colorectal Dis (2007) 1.18
Evaluation of the prenatal diagnosis of limb reduction deficiencies. EUROSCAN Study Group. Prenat Diagn (2000) 1.17
Adverse effects of prenatal methimazole exposure. Teratology (2001) 1.17
Quantitative molecular monitoring of human immunodeficiency virus type 1 activity during therapy with specific antiretroviral compounds. J Clin Microbiol (1995) 1.16
Activity of acyclic nucleoside phosphonate analogues against human immunodeficiency virus in monocyte/macrophages and peripheral blood lymphocytes. Biochem Biophys Res Commun (1991) 1.16
68Ga-DOTANOC: biodistribution and dosimetry in patients affected by neuroendocrine tumors. Eur J Nucl Med Mol Imaging (2007) 1.15
Molecular characterization and dynamics of hepatitis C virus replication in human fetal hepatocytes infected in vitro. Hepatology (1997) 1.15
Human mast cells take up and hydrolyze anandamide under the control of 5-lipoxygenase and do not express cannabinoid receptors. FEBS Lett (2000) 1.14
2',5'-Bis-O-(tert-butyldimethylsilyl)-3'-spiro-5''-(4''-amino-1'',2''- oxathiole-2'',2'-dioxide)pyrimidine (TSAO) nucleoside analogues: highlyselective inhibitors of human immunodeficiency virus type 1 that are targeted at the viral reverse transcriptase. Proc Natl Acad Sci U S A (1992) 1.14
Activity of the (R)-enantiomers of 9-(2-phosphonylmethoxypropyl)-adenine and 9-(2-phosphonylmethoxypropyl)-2,6-diaminopurine against human immunodeficiency virus in different human cell systems. Biochem Biophys Res Commun (1996) 1.13
Evolution of hypervariable region 1 of hepatitis C virus in primary infection. J Virol (1998) 1.13
Molecular studies in 20 submicroscopic neurofibromatosis type 1 gene deletions. Hum Mutat (1999) 1.13
Initial clinical experience with dideoxynucleosides as single agents and in combination therapy. Ann N Y Acad Sci (1990) 1.12
Quantitation of hepatitis C virus genome molecules in plasma samples. J Clin Microbiol (1994) 1.12
Anti-retroviral therapy of human immunodeficiency virus infection: current strategies and challenges for the future. Blood (1991) 1.12
Omphalocele and gastroschisis: a collaborative study of five Italian congenital malformation registries. Teratology (1993) 1.11
NF1 microdeletion syndrome: refined FISH characterization of sporadic and familial deletions with locus-specific probes. Am J Hum Genet (2000) 1.09
Nonneutralizing human antibody fragments against hepatitis C virus E2 glycoprotein modulate neutralization of binding activity of human recombinant Fabs. Virology (2001) 1.08
Nerve growth factor is an autocrine factor essential for the survival of macrophages infected with HIV. Proc Natl Acad Sci U S A (1999) 1.08
Highly favorable antiviral activity and resistance profile of the novel thiocarboxanilide pentenyloxy ether derivatives UC-781 and UC-82 as inhibitors of human immunodeficiency virus type 1 replication. Mol Pharmacol (1996) 1.08
Inhibition of replication of HIV in primary monocyte/macrophages by different antiviral drugs and comparative efficacy in lymphocytes. J Leukoc Biol (1997) 1.07
Antiretrovirus activity of a novel class of acyclic pyrimidine nucleoside phosphonates. Antimicrob Agents Chemother (2002) 1.06
Trans-activation of epidermal growth factor receptor gene by the hepatitis B virus X-gene product. Virology (1993) 1.04
Dynamics of molecular parameters of human immunodeficiency virus type 1 activity in vivo. J Virol (1994) 1.04
Host-specific modulation of the selective constraints driving human immunodeficiency virus type 1 env gene evolution. J Virol (1999) 1.04
Performance evaluation of an in-house human immunodeficiency virus type-1 protease-reverse transcriptase genotyping assay in Cameroon. Arch Virol (2011) 1.04
Evaluation of the prenatal diagnosis of neural tube defects by fetal ultrasonographic examination in different centres across Europe. J Med Screen (2000) 1.03
Diverse prevalence of large deletions within the OA1 gene in ocular albinism type 1 patients from Europe and North America. Hum Genet (2001) 1.03
Defective nef alleles in a cohort of hemophiliacs with progressing and nonprogressing HIV-1 infection. Virology (1999) 1.03
Mechanism of anti-HIV action of masked alaninyl d4T-MP derivatives. Proc Natl Acad Sci U S A (1996) 1.03
A randomized, controlled trial of a 24-month course of interferon alfa 2b in patients with chronic hepatitis B who had hepatitis B virus DNA without hepatitis B e antigen in serum. Hepatology (1997) 1.02
The safety of proton pump inhibitors in pregnancy: a multicentre prospective controlled study. Aliment Pharmacol Ther (2005) 1.02
Active hepatitis C virus infection in bone marrow and peripheral blood mononuclear cells from patients with mixed cryoglobulinaemia. Clin Exp Immunol (1994) 1.02
Clinical use of quantitative molecular methods in studying human immunodeficiency virus type 1 infection. Clin Microbiol Rev (1996) 1.02
Congenital diaphragmatic hernia: evaluation of prenatal diagnosis in 20 European regions. Ultrasound Obstet Gynecol (2002) 1.02
HIV infection in macrophage: role of long-lived cells and related therapeutical strategies. J Biol Regul Homeost Agents (1998) 1.02